Sugi Predict

Sugi Predict / Compounds / SCHEMBL25645281

SCHEMBL25645281

SCHEMBL25645281

CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(C)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 17/20 0.87
▸ AURKB Q96GD4 13/20 0.87
▸ EGFR P00533 4/20 0.87
▸ KDR P35968 4/20 0.87
▸ RIPK2 O43353 2/20 0.87
▸ LCK P06239 2/20 0.87
▸ LYN P07948 2/20 0.87
▸ RET P07949 2/20 0.87
▸ HCK P08631 2/20 0.87
▸ PDGFRB P09619 2/20 0.87
▸ KIT P10721 2/20 0.87
▸ PDGFRA P16234 2/20 0.87
▸ CSNK2A2 P19784 2/20 0.87
▸ FLT3 P36888 2/20 0.87
▸ MST1R Q04912 2/20 0.87
▸ MAP2K5 Q13163 2/20 0.87
▸ AURKC Q9UQB9 2/20 0.87
▸ MAP4K5 Q9Y4K4 2/20 0.87
▸ FYN P06241 1/20 0.87
▸ RAB6A P20340 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Barasertib SCHEMBL29720420 0.93 AURKA (1.00) AURKAAURKBEGFRKDRRIPK2
Barasertib SCHEMBL29368256 0.93 AURKA (1.00) AURKAAURKBEGFRKDRRIPK2
Barasertib SCHEMBL613582 0.93 AURKA (1.00) AURKAAURKBEGFRKDRRIPK2
SCHEMBL25645279 0.91 AURKA (0.86) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3490131 0.91 AURKA (0.96) AURKAAURKBEGFRKDRRIPK2
SCHEMBL4275319 0.90 AURKA (0.94) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3489414 0.89 AURKA (0.93) AURKAAURKBEGFRKDRRIPK2
SCHEMBL12132713 0.89 AURKA (0.92) AURKAAURKBEGFRKDRRIPK2
SCHEMBL613581 0.88 AURKA (0.91) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3862878 0.88 AURKA (0.90) AURKAAURKBEGFRKDRRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330086-A1 ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE SIGNAL PHARMACEUTICALS, LLC 2023-10-19 — — US disclosed
US-11660297-B2 Antiproliferative compounds and second active agents for combined use CELGENE CORPORATION (US) 2023-05-30 — — US disclosed
US-20230158037-A1 SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE CELGENE CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158037-A1 SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE DOT1L, CARM1, EZH2 AURKA 293/4885AURKB 397/4885EGFR 2294/4885
US-11660297-B2 Antiproliferative compounds and second active agents for combined use NEK4, NEK1, AURKB AURKA 24/4885AURKB 3/4885EGFR 1358/4885
US-20230330086-A1 ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE NEK4, AURKB, XPO1 AURKA 21/4885AURKB 2/4885EGFR 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.